Globeflex Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Globeflex Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,835	Closed	-$928K	–	521
2019 Q1	$928K	Buy	+11,835	New	+$897K	0.2%	178
2016 Q3	–	Sell	-2,244	Closed	-$167K	–	518
2016 Q2	$167K	Hold	2,244	–	–	0.05%	337
2016 Q1	$150K	Hold	2,244	–	–	0.04%	330
2015 Q4	$152K	Sell	2,244 -7,855	-78%	-$485K	0.04%	324
2015 Q3	$540K	Buy	+10,099	New	+$613K	0.12%	278
2014 Q3	–	Sell	-32	Closed	-$1K	–	611
2014 Q2	$1K	Sell	32 -29,128	-100%	-$1.18M	﹤0.01%	504
2014 Q1	$1.22M	Sell	29,160 -80	-0.3%	-$3.33K	0.14%	183
2013 Q4	$959K	Sell	29,240 -161	-0.5%	-$5.25K	0.12%	225
2013 Q3	$793K	Hold	29,401	–	–	0.1%	238
2013 Q2	$685K	Buy	+29,401	New	+$529K	0.09%	248

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Globeflex Capital's LGND Position: Q2 2019 in Review

Globeflex Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 11,835 shares — an estimated $928K sold.

Globeflex Capital first reported a position in LGND in Q2 2013 and held it in 10 quarters. The position peaked at $1.22M in Q1 2014. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Globeflex Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Globeflex Capital sold 11,835 Ligand Pharmaceuticals shares in Q2 2019, an estimated $928K.
Globeflex Capital first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Globeflex Capital's Ligand Pharmaceuticals position peaked at $1.22M in Q1 2014.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Globeflex Capital's 13F filing for Q2 2019, filed 12 Aug 2019.